Back

Does the presence of severe pulmonary hypertension affect survival at 5 years follow-up in patients who underwent TAVI for severe aortic stenosis?

31 August 2024 (17:00 - 17:50)
Organised by: Logo
Congress Presentation Part of: Impact of pulmonary hypertension on quality of life and survival Pulmonary Hypertension ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Hasan Mohiaddin

NIHR Biomedical Research Centre, Glenfield Hospital, Leicester (United Kingdom of Great Britain & Northern Ireland)

7 More presentations in this session

Presentation thumbnail
Comparison of pulmonary arterial risk assessment tools to predict mortality or morbidity in treatment naive and previously diagnosed patients.
Doctor C. Fauvel (Rouen, FR)
Abstract Slides Video
Presentation thumbnail
Prognostic value of follow-up hemodynamics after initial treatment in pulmonary arterial hypertension
Doctor D. Guarino (Bologna, IT)
Abstract Slides Video
Presentation thumbnail
Multiparametric risk predictions for morbidity and mortality in patients with pulmonary arterial hypertension: insights from a nation-wide registry
Professor C. Kaymaz (Istanbul, TR)
Abstract Slides Video
Presentation thumbnail
Acute vasoreactivity testing for severe pulmonary hypertension associated with lung disease
Doctor R. Takano (Suita, JP)
Abstract Slides Video
Presentation thumbnail
Health care utilisation in patients with mild pulmonary hypertension - EVIDENCE-PAH UK study
Doctor N. Karia (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Impact of pulmonary hypertension on quality of life and survival

The Event

Event poster

ESC Congress 2024

31 August 2024 17:00 CET
You may be interested in
thumbnail
Congress Session
Improving prognosis after TAVI
thumbnail
Congress Presentation
Periprocedural changes in systolic pulmonary artery pressure in transcatheter aortic valve implantation
thumbnail
Congress Presentation
Clinical, echocardiographic and haemodynamic predictors of morbidity and mortality in pulmonary hypertension: a nation-wide registry

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources